PMID- 33347003
OWN - NLM
STAT- MEDLINE
DCOM- 20210416
LR  - 20230814
IS  - 1524-4725 (Electronic)
IS  - 1076-0512 (Print)
IS  - 1076-0512 (Linking)
VI  - 47
IP  - 1
DP  - 2021 Jan 1
TI  - Safe and Effective Chin Augmentation With the Hyaluronic Acid Injectable Filler, 
      VYC-20L.
PG  - 80-85
LID - 10.1097/DSS.0000000000002795 [doi]
AB  - BACKGROUND: VYC-20L is a hyaluronic acid soft tissue filler with lidocaine 
      designed to restore facial volume. OBJECTIVE: Evaluate the safety and 
      effectiveness of VYC-20L in patients with chin retrusion. MATERIALS AND METHODS: 
      Adults with chin retrusion were randomized (3:1) to receive VYC-20L in the chin 
      at study onset (treatment group) or 6 months later (control group). The primary 
      effectiveness end point was >/=1-point improvement on the Allergan Chin Retrusion 
      Scale (ACRS) from baseline at Month 6. Safety assessments included injection site 
      responses (ISRs) and adverse events (AEs). RESULTS: VYC-20L was administered to 
      192 participants (treatment group, n = 144; control group, n = 48). At Month 6, 
      significantly more participants had an ACRS response in the treatment versus 
      control group (56.3% vs 27.5%; p = .0019). Effectiveness was also demonstrated by 
      the proportion of participants with improved/much improved Global Aesthetic 
      Improvement Scale scores and responses on the FACE-Q Satisfaction with Chin 
      questionnaire and FACE-Q Psychological Wellbeing module. Treatment benefit 
      remained evident at Month 12. Most common ISRs were tenderness (81.1%) and 
      firmness (75.1%). One participant (0.5%) discontinued the study due to 2 
      treatment-related serious AEs of facial cellulitis and injection site 
      inflammation, both resolved without sequelae. CONCLUSION: VYC-20L significantly 
      improved an ACRS response and was generally safe and well tolerated.
CI  - Copyright (c) 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on 
      behalf of the American Society for Dermatologic Surgery, Inc.
FAU - Beer, Kenneth
AU  - Beer K
AD  - Beer Dermatology, West Palm Beach, Florida.
FAU - Kaufman-Janette, Joely
AU  - Kaufman-Janette J
AD  - Skin Associates of South Florida, Coral Gables, Florida.
FAU - Bank, David
AU  - Bank D
AD  - The Center for Dermatology, Cosmetic & Laser Surgery, Mount Kisco, New York.
FAU - Biesman, Brian
AU  - Biesman B
AD  - Private Practice, Nashville, Tennessee.
FAU - Dayan, Steven
AU  - Dayan S
AD  - DeNova Research, Chicago, Illinois.
FAU - Kim, William
AU  - Kim W
AD  - Allergan plc, Irvine, California.
FAU - Chawla, Smita
AU  - Chawla S
AD  - Allergan plc, Irvine, California.
FAU - Schumacher, Andrew
AU  - Schumacher A
AD  - Allergan plc, Irvine, California.
LA  - eng
SI  - ClinicalTrials.gov/NCT02833077
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Dermatol Surg
JT  - Dermatologic surgery : official publication for American Society for Dermatologic 
      Surgery [et al.]
JID - 9504371
RN  - 0 (Dermal Fillers)
RN  - 0 (Gels)
RN  - 9004-61-9 (Hyaluronic Acid)
SB  - IM
CIN - Dermatol Surg. 2021 Feb 1;47(2):260. PMID: 33165080
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cellulitis/chemically induced
MH  - *Chin
MH  - *Cosmetic Techniques
MH  - Dermal Fillers/*administration & dosage/adverse effects
MH  - Esthetics
MH  - Female
MH  - Gels
MH  - Humans
MH  - Hyaluronic Acid/*administration & dosage/adverse effects
MH  - Injection Site Reaction
MH  - Male
MH  - Middle Aged
MH  - United States
PMC - PMC7752233
COIS- This study was sponsored by Allergan plc, Dublin, Ireland. Medical writing 
      assistance was provided to the authors by W. Kim of Allergan plc, Irvine, CA. All 
      authors met the ICMJE authorship criteria. Neither honoraria nor any other form 
      of compensation was provided for authorship. K. Beer, J. Kaufman-Janette, D. 
      Bank, and S. Dayan have received funding as an investigator, consultant, and 
      trainer for Allergan. B. Biesman has received consulting fees and research 
      funding from Allergan. W. Kim, S. Chawla, and A. Schumacher are employees of 
      Allergan plc and may own stock in the company.
EDAT- 2020/12/22 06:00
MHDA- 2021/04/17 06:00
PMCR- 2020/12/21
CRDT- 2020/12/21 14:40
PHST- 2020/12/21 14:40 [entrez]
PHST- 2020/12/22 06:00 [pubmed]
PHST- 2021/04/17 06:00 [medline]
PHST- 2020/12/21 00:00 [pmc-release]
AID - 00042728-202101000-00023 [pii]
AID - ds-00017-2020 [pii]
AID - 10.1097/DSS.0000000000002795 [doi]
PST - ppublish
SO  - Dermatol Surg. 2021 Jan 1;47(1):80-85. doi: 10.1097/DSS.0000000000002795.